Jiuwei Zhenxin Granules combined with lithium carbonate for insomnia during the remission phase of bipolar disorder
10.3760/cma.j.cn341190-20240522-00608
- VernacularTitle:九味镇心颗粒联合碳酸锂治疗双相情感障碍缓解期失眠的临床研究
- Author:
Yuezhong XU
1
;
Yan WANG
Author Information
1. 金华市妇幼保健院精神卫生科,金华 321000
- Publication Type:Journal Article
- Keywords:
Bipolar disorder;
Sleep initiation and maintenance disorders;
5-methoxytryptamine;
beta-Endorphin;
gamma-Aminobutyric acid;
Lithium carbonate
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(5):670-675
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of Jiuwei Zhenxin Granules combined with lithium carbonate in improving sleep quality in patients with insomnia during the remission phase of bipolar disorder. Methods:A total of 140 patients with insomnia during the remission phase of bipolar disorder, admitted to Jinhua Maternal and Child Health Care Hospital from March 2021 to March 2024, were selected for this study. This study used a retrospective research method. These patients were divided into a control group ( n = 70) and an observation group ( n = 70) according to the different treatment approaches. The control group received lithium carbonate sustained-release tablets, while the observation group received Jiuwei Zhenxin Granules in addition to the lithium carbonate treatment. The efficacy of the treatments for insomnia during the remission phase of bipolar disorder, as well as sleep quality and psychological status, was assessed. Polysomnography indicators of sleep quality were monitored. Serum levels of sleep-related neurotransmitters were measured. Adverse drug reactions were statistically analyzed. Results:In the observation group, the overall treatment efficacy for insomnia during the remission phase of bipolar disorder was significantly higher at 91.43% (64/70) compared with the control group at 71.43% (50/70) ( Z = 5.00, P < 0.001). After 4 weeks of treatment, the Pittsburgh Sleep Quality Index score, the Bech-Rafaelsen Mania Scale score, the Self-Rating Depression Scale score, and the Self-Rating Anxiety Scale score in the observation group were (7.62 ± 1.83), (22.07 ± 2.42), (26.35 ± 2.79), and (24.68 ± 2.65), respectively, which were significantly lower than those in the control group [(11.57 ± 2.14), (29.45 ± 3.11), (33.42 ± 3.81), (35.17 ± 3.92), t = 10.52, 12.84, 14.25, 17.34, all P < 0.001]. Within 4 weeks after treatment, the total sleep duration in the observation group was longer than that in the control group [(8.09 ± 1.17) hours vs. (6.37 ± 0.96) hours, P < 0.001], while the sleep latency in the observation group was shorter than that in the control group [(20.71 ± 2.28) minutes vs. (24.39 ± 2.62) minutes, P < 0.001]. Additionally, the number of awakenings was fewer in the observation group than that in the control group [(2.36 ± 0.37) times vs. (3.51 ± 0.42) times, P < 0.001]. After 4 weeks of treatment, the levels of sleep-related neurotransmitters serum serotonin, melatonin, β-endorphin, and γ-aminobutyric acid in the observation group were (0.51 ± 0.12) μg/L, (29.65 ± 3.27) ng/L, (18.49 ± 1.92) μg/L, and (287.45 ± 15.60) μg/L, respectively. These values were significantly higher than those in the control group [(0.43 ± 0.10) μg/L, (22.41 ± 2.54) ng/L, (14.05 ± 1.73) μg/L, and (239.06 ± 12.73) μg/L, t = -6.62, -13.43, -11.67, -18.52, all P < 0.001]. There was no significant difference in the incidence of adverse drug reactions between the observation and control groups [8.57% (6/70) vs. 11.43% (8/70), χ2 = 0.31, P = 0.573]. Conclusions:The combination of Jiuwei Zhenxin Granules and lithium carbonate can improve sleep quality, alleviate insomnia-related symptoms, and enhance overall prognosis in patients with insomnia during the remission phase of bipolar disorder by regulating neuroendocrine function.
